{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:40:02Z","timestamp":1789879202298,"version":"4.0.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI16\/02088"],"award-info":[{"award-number":["PI16\/02088"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI20\/00761"],"award-info":[{"award-number":["PI20\/00761"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/01804"],"award-info":[{"award-number":["PI22\/01804"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Systemic sclerosis (SSc)-specific autoantibodies allow the diagnosis and predict the prognosis of SSc patients with different clinical characteristics. The aim of this study was to describe new SSc-related autoantibodies by a novel protein immunoprecipitation (IP) assay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Serum samples and clinical data were collected from 307 SSc patients. Antinuclear autoantibodies were tested in all patients by indirect immunofluorescence (IIF) on HEp-2 cells. SSc-specific autoantibodies were evaluated with a commercial immunoblot and chemiluminescence immunoassay, and traditional RNA-IP. Patients negative for all these autoantibodies (n\u2009=\u200951) were further tested with a non-radioactive protein IP assay. Protein bands detected on SDS\u2013PAGE were then analysed by mass spectrometry (MS) and confirmed by western blot (WB). Additional 56 patients with nucleolar pattern by IIF were tested by protein IP-WB.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Five patients who underwent protein IP testing showed a 110-115kDa molecular weight band on SDS\u2013PAGE and a homogeneous nucleolar pattern by IIF. MS identified the bands as nuclear valosin-containing protein-like (NVL). An additional positive patient was detected by IP-WB. As compared with the remaining 101 negative patients, anti-NVL positive patients showed a greater prevalence of calcinosis (100% vs 18.9%, P\u2009&amp;lt;\u20090.001), and cancer (66.7% vs 8.9%, P\u2009=\u20090.002), with a particular association with synchronous cancer (OR\u2009=\u200916.3; P\u2009=\u20090.024).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We identified NVL as a new autoantibody target by a novel protein IP assay in SSc patients with a homogeneous nucleolar IIF pattern, testing negative for all known SSc-specific autoantibodies by commercial assays and RNA IP. Anti-NVL identifies a new clinical phenotype, characterized by calcinosis and cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead520","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T20:28:44Z","timestamp":1695932924000},"page":"2278-2283","source":"Crossref","is-referenced-by-count":12,"title":["Anti-nuclear valosin-containing protein-like autoantibody is associated with calcinosis and higher risk of cancer in systemic sclerosis"],"prefix":"10.1093","volume":"63","author":[{"given":"Janire","family":"Perurena-Prieto","sequence":"first","affiliation":[{"name":"Immunology Division, Vall d\u2019Hebron University Hospital (HUVH), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"},{"name":"Translational Immunology Group, Vall d\u2019Hebron Research Institute (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"},{"name":"Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona (UAB) , Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vi\u00f1as-Gim\u00e9nez","sequence":"additional","affiliation":[{"name":"Immunology Division, Vall d\u2019Hebron University Hospital (HUVH), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"},{"name":"Translational Immunology Group, Vall d\u2019Hebron Research Institute (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Sanz-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Immunology Division, Vall d\u2019Hebron University Hospital (HUVH), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"},{"name":"Translational Immunology Group, Vall d\u2019Hebron Research Institute (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Selva-O\u2019Callaghan","sequence":"additional","affiliation":[{"name":"Systemic Autoimmune Diseases Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital (HUVH), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Luis","family":"Callejas-Moraga","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital P\u00fablico de Monforte , Lugo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5964-536X","authenticated-orcid":false,"given":"Roger","family":"Colobran","sequence":"additional","affiliation":[{"name":"Immunology Division, Vall d\u2019Hebron University Hospital (HUVH), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"},{"name":"Translational Immunology Group, Vall d\u2019Hebron Research Institute (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"},{"name":"Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona (UAB) , Bellaterra, Spain"},{"name":"Department of Clinical and Molecular Genetics, Vall d\u2019Hebron University Hospital (HUVH), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Guill\u00e9n-Del-Castillo","sequence":"additional","affiliation":[{"name":"Systemic Autoimmune Diseases Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital (HUVH), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen P","family":"Sime\u00f3n-Aznar","sequence":"additional","affiliation":[{"name":"Systemic Autoimmune Diseases Unit, Internal Medicine Department, Vall d\u2019Hebron University Hospital (HUVH), Vall d\u2019Hebron Barcelona Hospital Campus , Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2024091719325633800_kead520-B1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"2024091719325633800_kead520-B2","first-page":"1573","article-title":"Criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","author":"Leroy","year":"2001","journal-title":"J Rheumatol"},{"key":"2024091719325633800_kead520-B3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/BOR.0000000000000904","article-title":"Scleroderma autoantibodies in guiding monitoring and treatment decisions","volume":"34","author":"Shah","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"2024091719325633800_kead520-B4","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"65","author":"Van Den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024091719325633800_kead520-B5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/rheumatology\/keab279","article-title":"Anti-RNPC-3 antibody predicts poor prognosis in patients with interstitial lung disease associated to systemic sclerosis","volume":"61","author":"Callejas-Moraga","year":"2021","journal-title":"Rheumatology"},{"key":"2024091719325633800_kead520-B6","first-page":"41","article-title":"Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain","volume":"37","author":"Callejas-Moraga","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2024091719325633800_kead520-B7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1006\/geno.1997.4856","article-title":"NVL: a new member of the AAA family of ATPases localized to the nucleus","volume":"44","author":"Germain-Lee","year":"1997","journal-title":"Genomics"},{"key":"2024091719325633800_kead520-B8","doi-asserted-by":"crossref","first-page":"21732","DOI":"10.1074\/jbc.M110.174680","article-title":"Structure and function of the N-terminal nucleolin binding domain of nuclear valosin-containing protein-like 2 (NVL2) harboring a nucleolar localization signal","volume":"286","author":"Fujiwara","year":"2011","journal-title":"J Biol Chem"},{"key":"2024091719325633800_kead520-B9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.bbrc.2015.07.032","article-title":"NVL2, a nucleolar AAA-ATPase, is associated with the nuclear exosome and is involved in pre-rRNA processing","volume":"464","author":"Yoshikatsu","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"2024091719325633800_kead520-B10","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.bbrc.2011.12.101","article-title":"The AAA-ATPase NVL2 is a telomerase component essential for holoenzyme assembly","volume":"417","author":"Her","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"2024091719325633800_kead520-B11","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.15537\/smj.2016.12.15972","article-title":"Roles of nucleolin. Focus on cancer and anti-cancer therapy","volume":"37","author":"Chen","year":"2016","journal-title":"Saudi Med J"},{"key":"2024091719325633800_kead520-B12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/ijms23010496","article-title":"RNA exosome component EXOSC4 amplified in multiple cancer types is required for the cancer cell survival","volume":"23","author":"Taniue","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024091719325633800_kead520-B13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13073-016-0324-x","article-title":"Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies","volume":"8","author":"Jafri","year":"2016","journal-title":"Genome Med"},{"key":"2024091719325633800_kead520-B14","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.4049\/jimmunol.146.7.2249","article-title":"Autoantibodies to nucleolin in systemic lupus erythematosus and other diseases","volume":"146","author":"Minota","year":"1991","journal-title":"J Immunol"},{"key":"2024091719325633800_kead520-B15","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1136\/annrheumdis-2020-218918","article-title":"Autoantibodies targeting telomere-associated proteins in systemic sclerosis","volume":"80","author":"Adler","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024091719325633800_kead520-B16","doi-asserted-by":"crossref","first-page":"102988","DOI":"10.1016\/j.jaut.2022.102988","article-title":"Identification of new telomere- and telomerase-associated autoantigens in systemic sclerosis","volume":"135","author":"Vulsteke","year":"2023","journal-title":"J Autoimmun"},{"key":"2024091719325633800_kead520-B17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12016-022-08931-3","article-title":"Clinical significance of antinucleolar antibodies: biomarkers for autoimmune diseases, malignancies, and others","volume":"63","author":"Satoh","year":"2022","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead520\/52346294\/kead520.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/8\/2278\/59148053\/kead520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/8\/2278\/59148053\/kead520.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T19:33:37Z","timestamp":1726601617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/8\/2278\/7285628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,9,28]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead520","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2023,9,28]]}}}